Table III.
Adverse events.
| Sorafenib (n=12) Grade (CTCAE v4.0) |
HAIC (n=8) Grade (CTCAE v4.0) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||
| Adverse events | 1 | 2 | 3 | 4 | Any | 3–4 | 1 | 2 | 3 | 4 | Any | 3–4 |
| Anemia | 4 | 1 | 5 (41.7) | 0 | 2 | 5 | 7 (87.5) | 0 | ||||
| Decreased WBC | 1 | 1 (8.3)a | 0 | 2 | 3 | 1 | 6 (75.0)a | 1 (12.5) | ||||
| Decreased neutrophil count | 1 | 1 (8.3)a | 0 | 3 | 2 | 1 | 6 (75.0)a | 1 (12.5) | ||||
| Decreasedlatelet count | 4 | 3 | 1 | 8 (66.7) | 1 (8.3) | 3 | 3 | 1 | 7 (87.5) | 4 (50.0) | ||
| Malaise | 5 | 2 | 7 (58.3) | 0 | 4 | 3 | 7 (87.5) | 0 | ||||
| Fever | 0b | 0 | 6 | 1 | 7 (87.5)b | 0 | ||||||
| Anorexia | 2 | 4 | 3 | 9 (75.0) | 3 (25.0) | 3 | 4 | 7 (87.5) | 0 | |||
| Nausea | 1 | 1 (8.3) | 0 | 2 | 2 (25.0) | 0 | ||||||
| Vomiting | 0 | 0 | 0 | 0 | ||||||||
| Diarrhea | 2 | 7 | 9 (75.0) | 0 | 2 | 2 (25.0) | 0 | |||||
| Mucositis | 1 | 2 | 3 (25.0) | 0 | 1 | 1 (12.5) | 0 | |||||
| Hand-foot syndrome | 4 | 1 | 4 | 9 (75.0)a | 4 (33.3) | 0a | 0 | |||||
| Hepatic encephalopathy | 1 | 1 (8.3) | 1 (8.3) | 0 | 0 | |||||||
| Ascites | 3 | 3 (25.0) | 0 | 0 | 0 | |||||||
| Bleeding | 0 | 0 | 0 | 0 | ||||||||
| Cardiological | 0 | 0 | 0 | 0 | ||||||||
| Hypertension | 2 | 3 | 3 | 8 (66.7)a | 3 (25.0) | 0a | 0 | |||||
| Pancreatitis | 0 | 0 | 0 | 0 | ||||||||
| Infection | 1 | 1 (8.3) | 0 | 2 | 2 (25.0) | 0 | ||||||
| Hyperbilirubinemia | 2 | 1 | 3 (25.0) | 0 | 2 | 2 (25.0) | 0 | |||||
| Hypoalbuminemia | 2 | 8 | 10 (83.3) | 0 | 1 | 5 | 6 (75.0) | 0 | ||||
| Increased AST | 6 | 6 (50.0) | 0 | 2 | 2 (25.0) | 0 | ||||||
| Increased ALT | 3 | 3 (25.0) | 0 | 1 | 1 (12.5) | 0 | ||||||
| Increased creatinine | 1 | 1 (8.3) | 0 | 1 | 2 | 3 (37.5) | 0 | |||||
| Increased serum amylase | 3 | 2 | 5 (41.7) | 0 | 0 | 0 | ||||||
The values represent number of events and the parenthetical data represent percentage values.
a
P<0.01;
b
P<0.001 (Fisher’s exact test).
CTCAE v4.0, Common Terminology Criteria for Adverse Events, version 4.0; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase.